Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.47 USD
Change Today +0.0088 / 1.91%
Volume 807.6K
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Key Developments

StemCells Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

StemCells Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $30,000 compared to $23,000 a year ago. Loss from operations was $9,273,000 compared to $7,960,000 a year ago. Net loss was $8,462,000 or $0.09 per basic and diluted share compared to $12,115,000 or $0.22 per basic and diluted share a year ago. Net loss from continuing operations was $8,462,000 against $1,971,000 a year ago. Revenue from continuing operations is primarily from royalties received under various licensing agreements. For the six months, the company reported total revenue of $51,000 compared to $47,000 a year ago. Loss from operations was $18,233,000 compared to $14,802,000 a year ago. Net loss was $17,812,000 or $0.22 per basic and diluted share compared to $19,735,000 or $0.36 per basic and diluted share a year ago. Net loss from continuing operations was $17,812,000 against $19,533,000 a year ago.

StemCells Inc. to Report Q2, 2015 Results on Aug 06, 2015

StemCells Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 06, 2015

StemCells Inc., Q2 2015 Earnings Call, Aug 06, 2015

StemCells Inc., Q2 2015 Earnings Call, Aug 06, 2015

StemCells, Inc. Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration

StemCells Inc. announced that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The Phase II trial is designed to evaluate both the safety and efficacy of the Company's proprietary HuCNS-SC® platform technology (purified human neural stem cells) for the treatment of geographic atrophy (GA), the most advanced form of dry age-related macular degeneration (AMD).

StemCells Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular Degeneration

StemCells Inc. announced that Dr. Stephen Huhn, its Vice President of Clinical Research and Chief Medical Officer, presented an overview of the Company's clinical translation efforts to date, including a summary of the safety and preliminary efficacy data from the Company's Phase I/II study investigating its proprietary HuCNS-SC cells (purified human neural stem cells) as a potential therapy for geographic atrophy, the most advanced form of dry age related macular degeneration (AMD). The summary was presented June 26, at 4:00 p.m. CEST, at the 2015 Annual Meeting of the International Society for Stem Cell Research (ISSCR) being held in Stockholm, Sweden. The Company's 15-patient, open-label, Phase I/II trial was designed to evaluate the safety and preliminary efficacy of sub-retinal HuCNS-SC cell transplantation in geographic atrophy (GA), the most advanced form of dry AMD. Multiple safety and efficacy assessments were incorporated into the study, including various assessments of visual function and measurements of disease status by direct retinal examination. The tests in the study included best-corrected visual acuity (BCVA), contrast sensitivity (CS), microperimetry for analysis of visual function, optical coherence tomography (OCT), and fundus autofluorescence (FAF) to measure the extent of the underlying geographic atrophy. The safety profile emerging from the Phase I/II study supports the recent initiation of the Company's Radiant Study, a Phase II controlled proof-of-concept trial. The BCVA and CS measurements for the majority of the patients in the study either improved or remained stable in the treated eye. OCT analysis showed increases in central subfield thickness and in macular volume in the treated eye relative to the untreated eye. The prospective analysis of both cohorts in the study showed GA growth rates in the study eye that were lower than those seen in the control eye, consistent with the previously reported interim findings for Cohort I alone. However, to further investigate the possible effect of the cells on GA and to inform future clinical development, the Company subsequently engaged a reading center to perform a separate post-hoc assessment. The separate assessments have revealed greater than anticipated variability in grading of the images. While the prospective analysis for both Cohorts continues to show a decrease in the rate of GA progression in the treated eye for the majority of the patients, the post-hoc analysis did not reveal a similar trend.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $0.47 USD +0.0088

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.13 USD 0.00
Bioheart Inc $0.0032 USD 0.00
Biorestorative Therapies Inc $8.00 USD -0.25
IntelliCell BioSciences Inc $0.0002 USD 0.0001
Opexa Therapeutics Inc $0.44 USD -0.0104
View Industry Companies
 

Industry Analysis

STEM

Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.1x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.